Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.PRNewsWire • 12/16/24
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory BoardPRNewsWire • 12/05/24
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory BoardPRNewsWire • 11/27/24
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 millionPRNewsWire • 11/22/24
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024PRNewsWire • 10/31/24
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH AntibodiesPRNewsWire • 09/16/24
IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.GlobeNewsWire • 09/09/24
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000PRNewsWire • 08/21/24
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing ShareholderPRNewsWire • 08/20/24
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23PRNewsWire • 08/15/24
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common EquityPRNewsWire • 08/13/24
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAbPRNewsWire • 07/23/24
Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment resultsInvezz • 07/15/24
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin modelPRNewsWire • 07/15/24
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to EquityPRNewsWire • 07/08/24
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing RequirementsPRNewsWire • 07/03/24
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.PRNewsWire • 06/13/24
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity RequirementPRNewsWire • 06/07/24
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining CompliancePRNewsWire • 05/24/24
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business UpdatePRNewsWire • 05/15/24
